Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Neuromuscular Disorders Market Value Growth And Long-Term Outlook
The neuromuscular disorders market size has shown significant expansion in recent years. It is projected to grow from $8.31 billion in 2025 to $8.98 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 8.0%. Historically, this growth can be attributed to the increasing prevalence of genetic neuromuscular conditions, rising awareness about early diagnosis and treatment options, a growing demand for effective therapies for rare disorders, increasing research initiatives in muscular dystrophy and ALS, and the rising adoption of advanced diagnostic technologies.
The neuromuscular disorders market is projected to experience substantial growth over the next few years, with its size expected to reach $12.07 billion in 2030, reflecting a compound annual growth rate (CAGR) of 7.7%. This expansion during the forecast period is attributable to increasing patient advocacy and support group activities, a rising demand for biologics and gene therapies, growing recognition of neuromuscular disorders in children, escalating government initiatives for rare disease management, and an increasing focus on home-based care and rehabilitation services. Foremost trends anticipated in this period include advances in gene-editing technologies for targeted therapies, innovations in RNA-based treatment platforms, the incorporation of artificial intelligence for expedited neuromuscular diagnosis, progress in stem-cell-based regenerative treatments, and novel developments in wearable devices for continuous patient monitoring.
Get A Free Sample Report With In-Depth Market Insights:
Neuromuscular Disorders Market Expansion Drivers: What’s Shaping Future Growth?
The escalating need for personalized medicine is projected to stimulate the expansion of the neuromuscular disorders market moving forward. Personalized medicine represents a medical methodology focused on adapting treatments for individual patients, drawing upon their genetic makeup, environmental influences, and lifestyle habits to achieve optimal results and enhance care. The increased preference for personalized medicine stems from breakthroughs in genomic technologies, which facilitate the precise identification of genetic variations and the development of customized treatments for individuals. This approach significantly improves the management of neuromuscular disorders by tailoring therapies based on each individual’s genetic, molecular, and physiological profiles. It leads to better patient outcomes by enabling targeted interventions, boosting efficacy, and minimizing adverse reactions. For instance, in February 2024, the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, revealed that the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, marking a considerable increase from the 12 approved in 2022. Consequently, the growing demand for personalized medicine is propelling the growth of the neuromuscular disorders market.
Neuromuscular Disorders Market Segmentation And Category Overview
The neuromuscular disorders market covered in this report is segmented –
1) By Disease Type: Spinal Muscular Atrophy (SMA), Amyotrophic Lateral Sclerosis (ALS), Duchenne Muscular Dystrophy (DMD), Myasthenia Gravis, Other Muscular Dystrophies
2) By Product Type: Pharmaceuticals, Biologics, Diagnostic Tools, Assistive Devices
3) By Route of Administration: Oral, Injectable, Other Route of Administrations
4) By Treatment: Gene Therapy, Drug Therapy, RNA-Based Therapy, Enzyme Replacement Therapy, Physical Therapy And Rehabilitation, Respiratory Care
Subsegments:
1) By Spinal Muscular Atrophy: SMA Type 1, SMA Type 2, SMA Type 3, SMA Type 4, SMA with Respiratory Distress (SMARD)
2) By Amyotrophic Lateral Sclerosis: Sporadic ALS, Familial ALS, Limb-Onset ALS, Bulbar-Onset ALS, Respiratory-Onset ALS
3) By Duchenne Muscular Dystrophy: Early-Onset DMD, Late-Onset DMD, Exon Deletion Mutations, Exon Duplication Mutations, Point Mutations
4) By Myasthenia Gravis: Generalized Myasthenia Gravis, Ocular Myasthenia Gravis, Seropositive MG, MuSK-Positive MG, Seronegative MG
5) By Other Muscular Dystrophies: Becker Muscular Dystrophy (BMD), Limb-Girdle Muscular Dystrophy (LGMD), Facioscapulohumeral Muscular Dystrophy (FSHD), Congenital Muscular Dystrophies, Myotonic Dystrophy
Neuromuscular Disorders Market Strategic Trends: What Defines The Next Growth Phase?
Leading companies operating within the neuromuscular disorders market are concentrating on creating sophisticated treatments, such as gene replacement therapies, to target the underlying genetic origins of conditions like Duchenne muscular dystrophy and spinal muscular atrophy. Gene replacement therapy involves engineered biological products designed to deliver functional copies of defective genes, aiming to restore or enhance muscle function in patients suffering from inherited neuromuscular conditions, thereby presenting a potential single-dose intervention that lessens the demand for continuous long-term treatment. For instance, in November 2025, Novartis, a pharmaceuticals company based in Switzerland, secured approval from the US Food and Drug Administration (FDA) for Itvisma (onasemnogeneabeparvovec-brve), which represents the initial and sole gene replacement therapy available for treating children two years of age and older, teens, and adults diagnosed with spinal muscular atrophy (SMA) who possess a confirmed mutation in the survival motor neurone 1 (SMN1) gene. This therapy is specifically formulated to address the genetic root cause of SMA through a single, unvarying dosage that does not necessitate adjustments based on body weight or age. Itvisma has the capacity to improve motor function by replacing the SMN1 gene, which could diminish the requirement for ongoing medication when used alongside other existing therapies for this demographic.
Neuromuscular Disorders Market Leading Players And Competitive Positioning
Major companies operating in the neuromuscular disorders market are AbbVie Inc., Novartis AG, Takeda Pharmaceutical Company Limited, The Trustees of the University of Pennsylvania, Biogen Inc., Sarepta Therapeutics Inc., argenx SE, PTC Therapeutics Inc., Catalyst Pharmaceuticals Inc., Mayo Clinic Laboratories, Fulgent Genetics Inc., Dyne Therapeutics Inc., The Regents of the University of California, GeneDx LLC, PepGen Inc., Centogene N.V., Scholar Rock Holding Corporation, Solid Biosciences Inc., Vita Therapeutics Inc., NMD Pharma A/S, Cytokinetics Incorporated, Sudo Biosciences Inc.
View The Full Neuromuscular Disorders Market Report:
Neuromuscular Disorders Market Regional Distribution: Which Areas Power Market Growth?
North America was the largest region in the neuromuscular disorders market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuromuscular disorders market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model